uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Urology.
Show others and affiliations
2013 (English)In: BMC Urology, ISSN 1471-2490, Vol. 13, 17- p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Low nuclear expression of the RNA-binding motif protein 3 (RBM3) has previously been found to be associated with poor prognosis in several cancer forms e.g. breast, ovarian, colorectal, prostate cancer and malignant melanoma. The aim of this study was to examine the prognostic impact of RBM3 expression in urinary bladder cancer.

METHODS: Immunohistochemical RBM3 expression was examined in tumours from 343 patients with urothelial bladder cancer. Chi-square and Spearman's correlation tests were applied to explore associations between RBM3 expression and clinicopathological characteristics. The impact of RBM3 expression on disease-specific survival (DSS), 5-year overall survival (OS) and progression-free survival (PFS) was assessed by Kaplan-Meier analysis and Cox proportional hazards modelling.

RESULTS: Reduced nuclear RBM3 expression was significantly associated with more advanced tumour (T) stage (p <0.001) and high grade tumours (p=0.004). Negative RBM3 expression was associated with a significantly shorter DSS (HR=2.55; 95% CI 1.68-3.86)) and 5-year OS (HR=2.10; 95% CI 1.56-2.82), also in multivariable analysis (HR=1.65; 95% CI 1.07-2.53 for DSS and HR=1.54; 95% CI 1.13-2.10 for 5-year OS). In patients with Ta and T1 tumours expressing reduced RBM3 levels, Kaplan-Meier analysis revealed a significantly shorter PFS (p=0.048) and 5-year OS (p=0.006).

CONCLUSION: Loss of RBM3 expression is associated with clinically more aggressive tumours and an independent factor of poor prognosis in patients with urothelial bladder cancer and a potentially useful biomarker for treatment stratification and surveillance of disease progression.

Place, publisher, year, edition, pages
2013. Vol. 13, 17- p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-199938DOI: 10.1186/1471-2490-13-17ISI: 000318004100001PubMedID: 23565664OAI: oai:DiVA.org:uu-199938DiVA: diva2:621823
Available from: 2013-05-17 Created: 2013-05-17 Last updated: 2013-05-27Bibliographically approved

Open Access in DiVA

fulltext(1525 kB)76 downloads
File information
File name FULLTEXT01.pdfFile size 1525 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Segersten, UlrikaMalmström, Per-Uno
By organisation
In the same journal
BMC Urology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 76 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 323 hits
ReferencesLink to record
Permanent link

Direct link